258 related articles for article (PubMed ID: 22150310)
1. C/EBPα dysregulation in AML and ALL.
Paz-Priel I; Friedman A
Crit Rev Oncog; 2011; 16(1-2):93-102. PubMed ID: 22150310
[TBL] [Abstract][Full Text] [Related]
2. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
[TBL] [Abstract][Full Text] [Related]
3. CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-kappaB p50.
Paz-Priel I; Cai DH; Wang D; Kowalski J; Blackford A; Liu H; Heckman CA; Gombart AF; Koeffler HP; Boxer LM; Friedman AD
Mol Cancer Res; 2005 Oct; 3(10):585-96. PubMed ID: 16254192
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the C/EBPα signaling pathway in acute myeloid leukemia (Review).
Song G; Wang L; Bi K; Jiang G
Oncol Rep; 2015 May; 33(5):2099-106. PubMed ID: 25760953
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias.
Gombart AF; Hofmann WK; Kawano S; Takeuchi S; Krug U; Kwok SH; Larsen RJ; Asou H; Miller CW; Hoelzer D; Koeffler HP
Blood; 2002 Feb; 99(4):1332-40. PubMed ID: 11830484
[TBL] [Abstract][Full Text] [Related]
6. A C-terminal mutant of CCAAT-enhancer-binding protein α (C/EBPα-Cm) downregulates Csf1r, a potent accelerator in the progression of acute myeloid leukemia with C/EBPα-Cm.
Togami K; Kitaura J; Uchida T; Inoue D; Nishimura K; Kawabata KC; Nagase R; Horikawa S; Izawa K; Fukuyama T; Nakahara F; Oki T; Harada Y; Harada H; Aburatani H; Kitamura T
Exp Hematol; 2015 Apr; 43(4):300-8.e1. PubMed ID: 25534203
[TBL] [Abstract][Full Text] [Related]
7. C/EBPα in normal and malignant myelopoiesis.
Friedman AD
Int J Hematol; 2015 Apr; 101(4):330-41. PubMed ID: 25753223
[TBL] [Abstract][Full Text] [Related]
8. C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription.
Du M; Wang M; Liu M; Fu S; Lin Y; Huo Y; Yu J; Yu X; Wang C; Xiao H; Wang L
J Exp Clin Cancer Res; 2024 Mar; 43(1):79. PubMed ID: 38475919
[TBL] [Abstract][Full Text] [Related]
9. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).
Preudhomme C; Sagot C; Boissel N; Cayuela JM; Tigaud I; de Botton S; Thomas X; Raffoux E; Lamandin C; Castaigne S; Fenaux P; Dombret H;
Blood; 2002 Oct; 100(8):2717-23. PubMed ID: 12351377
[TBL] [Abstract][Full Text] [Related]
10. CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex.
Schmidt L; Heyes E; Scheiblecker L; Eder T; Volpe G; Frampton J; Nerlov C; Valent P; Grembecka J; Grebien F
Leukemia; 2019 Jul; 33(7):1608-1619. PubMed ID: 30679799
[TBL] [Abstract][Full Text] [Related]
11. Gain-of-Function Effects of N-Terminal CEBPA Mutations in Acute Myeloid Leukemia.
Schmidt L; Heyes E; Grebien F
Bioessays; 2020 Feb; 42(2):e1900178. PubMed ID: 31867767
[TBL] [Abstract][Full Text] [Related]
12. Infrequent hypermethylation of CEBPA promotor in acute myeloid leukaemia.
Chim CS; Wong AS; Kwong YL
Br J Haematol; 2002 Dec; 119(4):988-90. PubMed ID: 12472578
[TBL] [Abstract][Full Text] [Related]
13. Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models.
Kato N; Kitaura J; Doki N; Komeno Y; Watanabe-Okochi N; Togami K; Nakahara F; Oki T; Enomoto Y; Fukuchi Y; Nakajima H; Harada Y; Harada H; Kitamura T
Blood; 2011 Jan; 117(1):221-33. PubMed ID: 20884804
[TBL] [Abstract][Full Text] [Related]
14. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.
Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Zimmermann M; Peeters JK; Valk PJ; Balgobind BV; Sonneveld E; Kaspers GJ; de Bont ES; Trka J; Baruchel A; Creutzig U; Pieters R; Reinhardt D; Zwaan CM
Haematologica; 2011 Mar; 96(3):384-92. PubMed ID: 21134981
[TBL] [Abstract][Full Text] [Related]
15. Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML.
Heyes E; Schmidt L; Manhart G; Eder T; Proietti L; Grebien F
Leukemia; 2021 Sep; 35(9):2526-2538. PubMed ID: 33623142
[TBL] [Abstract][Full Text] [Related]
16. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.
Pabst T; Mueller BU; Zhang P; Radomska HS; Narravula S; Schnittger S; Behre G; Hiddemann W; Tenen DG
Nat Genet; 2001 Mar; 27(3):263-70. PubMed ID: 11242107
[TBL] [Abstract][Full Text] [Related]
17. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
18. C/EBPalphap30, a myeloid leukemia oncoprotein, limits G-CSF receptor expression but not terminal granulopoiesis via site-selective inhibition of C/EBP DNA binding.
Cleaves R; Wang QF; Friedman AD
Oncogene; 2004 Jan; 23(3):716-25. PubMed ID: 14737106
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis.
Quintana-Bustamante O; Lan-Lan Smith S; Griessinger E; Reyal Y; Vargaftig J; Lister TA; Fitzgibbon J; Bonnet D
Leukemia; 2012 Jul; 26(7):1537-46. PubMed ID: 22371011
[TBL] [Abstract][Full Text] [Related]
20. C/EBPα deregulation as a paradigm for leukemogenesis.
Pulikkan JA; Tenen DG; Behre G
Leukemia; 2017 Nov; 31(11):2279-2285. PubMed ID: 28720765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
